CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and ...

Researchers create a biomimetic model to study wound healing in burn and laceration wounds. The team designed an in vitro model system made of fibroblasts embedded in a collagen hydrogel. Wounds were ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2. The ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...

CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its ...

Authors review the indications and contraindications, as well as the risks and benefits, of hyperbaric oxygen therapy in chronic wound management. Wounds that fail to proceed through the normal phases ...

These findings represent a crucial advancement in wound care, paving the way for more effective treatment options and improved patient outcomes. To address this, researchers conducted a study using ...